Asgharzade Samira, Tabatabaiefar Mohammad Amin, Mohammadi-Asl Javad, Chaleshtori Morteza Hashemzadeh
Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Pediatr Otorhinolaryngol. 2018 May;108:8-11. doi: 10.1016/j.ijporl.2018.01.006. Epub 2018 Jan 31.
Recent studies have confirmed the utility of targeted next-generation sequencing (NGS), providing a remarkable opportunity to find variants in known disease genes, especially in genetically heterogeneous disorders such as hearing loss (HL).
After excluding mutations in the most common autosomal recessive non-syndromic HL (ARNSHL) genes via Sanger sequencing and genetic linkage analysis, we performed NGS in the proband an Iranian family with ARNSHL. The NimbleGen sequence capture array captures codingsequences (CDSs) and 100 bp of the flanking sequence of 129 common deafness genes (cat# Oto-DA3). NGSwas performed on the IlluminaHiSeq2000. BWA, SAMtools, Picard, GATK, Variant Tools, ANNOVAR, and IGV were applied for Bioinformatics analyses. Data filtering with allele frequencies (<5% in the 1000 Genomes Project and 5400 NHLBI exomes) and PolyPhen2/SIFTscores (>0.95) prioritized 1indel (insertions/deletions) and 3 missense variants in this family. Eventually, Sanger sequencing, segregation pattern, the frequency in 50 healthy matched normal controls, and evolutionary conservation of amino acid residues revealed the pathogenic variant.
We identified a novel missenseGIPC3 mutation, c.472G > A (p.Glu158 Lys). The pathogenicity of GIPC3c.472G > A was supported by its absence in the population databases and the healthy-matched controls.Sanger sequencing confirmed co-segregation of the mutation with HL.
This study is the first report of the contribution of theGIPC3 gene to HL in the Iranian population.Targeted NGS allows easier detection of mutations in relatively uncommon deafness genes in families with ARNSHL.
近期研究证实了靶向新一代测序(NGS)的实用性,为在已知疾病基因中发现变异提供了显著契机,尤其是在遗传性异质性疾病如听力损失(HL)中。
通过桑格测序和基因连锁分析排除最常见的常染色体隐性非综合征性HL(ARNSHL)基因中的突变后,我们对一个患有ARNSHL的伊朗家系的先证者进行了NGS。NimbleGen序列捕获阵列捕获129个常见耳聋基因(货号Oto - DA3)的编码序列(CDS)及其侧翼序列的100 bp。在IlluminaHiSeq2000上进行NGS。使用BWA、SAMtools、Picard、GATK、Variant Tools、ANNOVAR和IGV进行生物信息学分析。根据等位基因频率(在千人基因组计划和5400个NHLBI外显子组中<5%)和PolyPhen2/SIFT评分(>0.95)进行数据筛选,该家系中有1个插入/缺失(indel)和3个错义变异被优先考虑。最终,桑格测序、分离模式、50名健康匹配正常对照中的频率以及氨基酸残基的进化保守性揭示了致病变异。
我们鉴定出一个新的错义GIPC3突变,c.472G > A(p.Glu158 Lys)。人群数据库和健康匹配对照中均未发现GIPC3 c.472G > A,支持了其致病性。桑格测序证实该突变与HL共分离。
本研究首次报道了GIPC3基因对伊朗人群HL的影响。靶向NGS使在患有ARNSHL的家系中更容易检测相对罕见的耳聋基因中的突变。